Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liandan mixture
- Development stage
- Unknown
- Lead developer
- Wuhan Women and Children's Health Care Center
- Administration
- Oral
01
Overview
Liandan mixture is a Traditional Chinese Medicine (TCM) liquid formulation developed by Wuhan Children's Hospital for the treatment of infantile cholestasis and the prevention of hepatic cholestatic fibrosis. The mixture is hypothesized to exert its therapeutic effects by antagonizing oxidative stress, which is a key driver in the progression of liver damage and fibrosis during cholestasis. Clinical research, including trial ChiCTR2000041352, has focused on evaluating the mixture's ability to improve liver function and reduce fibrotic markers in pediatric patients by mitigating oxidative stress and potentially promoting bile flow.
- Other names
- Liandan Heji连胆合剂
Beyond the preview
Go deeper on Liandan mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liandan mixture.